Kornimate/medical-research-clean huggingface dataset:
is tuberculin skin testing effective in screening for latent tuberculosis in patients with hiv?

Conditions: Latent Tuberculosis; HIV Infections

Summary: hiv infection highly increases the risk of progression of latent tuberculosis (tb) to active disease that therapy is recommended for all ppd-positive, hiv-infected patients, regardless of age. sensitivity of the ppd testing is, however, dependent on a normal t cell function. therefore, an accurate and reliable method for detection of latent tuberculosis in patients with hiv is urgently needed. this prospective study will examine the utility of interferon-gamma (ifn-γ) based assay, t-spot.tb,for detection of tb in hiv-infected individuals.


Eligibility criteria:
inclusion criteria * adult individuals with confirmed hiv infection exclusion criteria: * patients who are on inh treatment * patients who have a positive ppd test within 1 year of study enrollment * individuals with blistering or ulcerating skin disorder * pregnant women * patients who were given blood transfusion within 6 weeks prior to enrollment

Keywords: latent tuberculosis hiv ifn-γ based assay
early administration of vitamin c in patients with sepsis or septic shock in emergency departments

Conditions: Sepsis; Septic Shock; Sepsis, Severe

Summary: in this clinical trial the effect of early administration of vitamin c is investigated in patients admitted at the emergency department with sepsis or septic shock. when a patient has sepsis, his/her body is causing damage to its own tissues and organs as result of an infection. this can lead to septic shock. the patient has a low blood pressure, his/her organs stop working and the patient may even die. the aim of this trial is to investigate the efficiency of vitamin c in sepsis and septic shock. vitamin c is a vitamin present in various foods and has been approved as dietary supplement by the belgian authorities. over the years it has been proven that vitamin c is very safe. in addition, several studies have shown that vitamin c can also have a protective effect. it can reduce organ damage and increase survival rates. although several studies suggest that vitamin c can help fight sepsis, it is not yet used in practice. this belgian trial, in which several hospitals participate, hopes to provide a clear answer to the question: "should vitamin c be administered to patients admitted in an emergency department with sepsis or septic shock?"


Eligibility criteria:
inclusion criteria: * patient has a 'suspected infection': this requires the combination of antibiotic administration and body fluid cultures within the first 6 hours after emergency department presentation. * patient has a news score ≥ 5. exclusion criteria: * patient (≥18 years old) or legally authorized representative didn't provide informed consent. delayed informed consent can be applied in cases where the patient is critically ill and no lar is available. * antibiotic administration as a single dose or as a prophylactic treatment. * antibiotics administered without an accompanying body fluid culture according to the timeframe (within 6 hours after emergency department presentation). * 'do no intubate' or 'comfort measures only' status. * failure to randomize within 6 hours after emergency department presentation. * weight \< 45 kg. * pregnant or breastfeeding. * known allergy for vitamin c. * known history of oxalate nephropathy or hyperoxaluria. * known history of glucose-6-phosphate dehydrogenase deficiency. * known history of chronic iron overload due to iron storage and other diseases. * the patient is already on iv steroids for a reason other than septic shock. * proven active covid-19 infection (positive swab and/or ct scan positive for covid-19 within 14 days prior to or at ed presentation). * participation in an interventional trial with an investigational medicinal product (imp) or device

Keywords: vitamin c ascorbic acid sepsis septic shock rct
evaluate the accuracy of breast mri biopsy in diagnosing a complete tumor response for some women following neoadjuvant chemotherapy for breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to test the ability of a breast mri biopsy to accurately diagnose a complete tumor response to the neoadjuvant chemotherapy (nac) that the patient just finished. numerous studies have shown that mri has the highest accuracy for diagnosing a complete tumor response. the investigator wants to see if in a certain group of women who's breast cancer is no longer visible on the post-treatment mri that the biopsy specimens from a mri guided biopsy will accurately diagnose a complete tumor response to treatment which may in the future make breast surgery unnecessary in some women.


Eligibility criteria:
inclusion criteria: * women age 18 years or older * confirmed histologic diagnosis of operable her2 overexpressing (er\<10%, pr\<10%, and her2 2+ or fish amplified) or triple negative (er\<10%, pr\<10%, and her2 0/1+ or 2+/fish not amplified) or er positive invasive ductal or invasive lobular breast cancer including mskcc pathology confirmation * operable breast cancer treated with nac undergoing either breast conservation or total mastectomy who have had a post-nac clinical bilateral breast mri demonstrating a complete imaging response, which is defined as no residual tumor enhancement. * no indication of distant metastases (m0) * tumor site amenable to mri guided biopsy as determined by the radiologist * definitive surgery being performed at mskcc within within 0-60 days of completing nac * ecog performance status score of 0 to ≤ 2 and or kps performance status score of 80% to 100% * women of childbearing potential (wocbp) must not be pregnant. * women must not be breastfeeding * willing and able to provide informed consent and adhere to the study visit schedule and plan as specified in this protocol exclusion criteria: * medical history and concurrent disease: * prior history of treated breast cancer * any underlying medical or psychiatric conditions, which in the opinion of the investigator, will make performing the study intervention hazardous or obscure the interpretation of the results * prohibited treatments and/or therapies: * prior history of breast cancer surgery and/or radiotherapy.

Keywords: mri biopsy 17-390
the use of blood biochemical markers for diagnostics of heart muscle diseases

Conditions: Heart Failure; Heart Dilation; Left Ventricular Hypertrophy

Summary: the aim of the study is to determine the analytical characteristics of the microrna enzymatic immunoassay (mireia) method and to determine various relations among mirna biomarkers and heart failure (hf) with reduced ejection fraction(hfref). the investigators assume that there are correlations between levels of selected mirna and hfref. these correlations provide information to formulate pathophysiological conclusions, which will significantly contribute to early diagnostics and also the treatment of this disease.

heart failure presents a significant diagnostic and treatment problem. the mortality in the czech republic related to this condition is high. the current treatment strategy consists of the administration of medication to patients, in order to attenuate the clinical manifestations of the disease and to influence the overall survival of patients suffering from this condition. another treatment option is a mini-invasive procedure, with implantation of a pacemaker with biventricular stimulation, or transplantation of the heart. despite these treatment options, the mortality of patients due to heart failure remains high, and new approaches are being studied for the diagnostics and treatment of heart failure. factors that may play an important role in earlier diagnostics are mirna. these molecules are located in the circulating blood. they are being described as suitable prognostic markers of heart failure, which may contribute to earlier diagnostics and bring a better understanding of processes going on in the human body. in the study, the authors will take blood samples in order to analyze the presence of mirna. these levels of mirna will be compared with heart ultrasound parameters of hf patients and healthy control subjects.

Eligibility criteria:
inclusion criteria (patient group): * left ventricle ejection fraction (ef lv) equal or less than 40% * age between 18-80 years inclusion criteria (control group): * normal ef lv (left ventricular ejection fraction) * no structural cardiac abnormalities * age between 18-80 years. exclusion criteria: * recent myocardial infarction * recent percutaneous coronary intervention (pci) * recent decompensation of chronic heart failure * chronic kidney disease with need for haemodialysis * creatin level over 450 umol/l * signs of acute or chronic inflammation with crp (c-reactive protein) over 20 mg/l * patient with a known tumour * history of cardiovascular disease * diabetes mellitus * severe liver and kidney disease * bnp (brain natriuretic peptide) \> 250 pg/ml or ntprobnp \> 500 pg/ml for males and 750 pg/ml for females * signs of acute or chronic inflammation with crp over 20 mg/l

Keywords: microrna immunomethods heart failure biomarkers
the effect of nonverbal vocalisations on pain tolerance

Conditions: Healthy

Summary: humans produce non-verbal vocalizations (shouting, growling, screaming), laughter, ...) in various contexts that are likely to perform biological functions. and important social issues. yet despite their importance in the human vocal repertoire, the mechanisms and functions of non-verbal vocalizations remain little studied and poorly understood including in humans. in this context, the investigators wish to examine how the production of vocalizations non-verbal communication influences pain tolerance in healthy adults.

humans produce nonverbal vocalisations such as screams, grunts, roars, cries and laughter across a variety of contexts. yet despite the prominence and apparent importance of these nonverbal sounds in human communication, the investigators still know very little about their influence on human perception and behaviour. that's why, in this study, the investigators will examine specifically the influence of nonverbal vocal production on pain tolerance. the remainder of the study will involve up to three trials of a pain tolerance (cold pressor) task, during which the investigators will ask participants to produce vocalisations (e.g., screams or words) while submerging the participant's hand in bath of circulating cold water. the results of the study will contribute to our theoretical understanding of the functions of nonverbal vocal communication in humans, in particular the influence of nonverbal vocal production (i.e., yelling) on pain tolerance.

Eligibility criteria:
inclusion criteria: * participant in good health * affiliated or entitled participant in a social security scheme * participant who has received informed information about the study and has co-signed a consent to participate in the study with the investigator. exclusion criteria: * chronic pain * high blood pressure or poor circulation * cardiac or vascular disease, or a heart condition (including symptoms of raynaud's syndrome) * allergy or hypersensitivity to cold * diabetes * epilepsy * pregnancy * recent serious injury * neurological or psychiatric condition known to affect pain tolerance (e.g., peripheral neuropathy, schizophrenia) * history of fainting or seizures * history of frostbite * chronic smoker (more than 10 cigarettes a day)

Keywords: nonverbal vocal communication pain tolerance cold pressor test nociception level index video pupillometry
health related quality of life following hepatectomy for colorectal liver metastasis: global and disease specific changes over time

Conditions: Colorectal Liver Metastasis

Summary: this study is being done to learn more about health related quality of life factors in people having surgery for colorectal liver metastasis. the investigators will look at how these factors may change over time. the information gained from this study will help the investigators to understand the long-term effects that cancer treatments have on the health related quality of life of patients. this information is of high value and will help doctors talk to patients about the possible effects of their operations. while many patients live a long time after such operations, the studies that have been done do not tell the full story of what patients go through after surgery. this study will help us to understand cancer treatment from the patient's perspective. it will also help cancer patients make better decisions about their treatment options and will help them know what to expect after the operation.


Eligibility criteria:
inclusion criteria: * diagnosis of colorectal cancer liver metastases (crlm) * \> 18 years of age * absence of unresectable extrahepatic disease * no previous liver surgery for crlm * clinical risk score (crs) \>/= 3 or \> 4 tumors * crs includes the following variables; * lymph node positive primary * disease free interval \<12 months * cea level \>200ng/ml (highest cea level within 6 months prior to surgery, not including day of surgery) * tumor size \> 5cm * number of tumors \>1(based on most recent scan or pathology before liver resection) * each variable is given a score of one and summed to give final crs * clinical risk score (crs) \< 3 with pending variables that cannot be determined preoperatively * if crs is still \< 3 postoperatively, these patients will be excluded and replaced (inevaluable). * ability to read and write in english * undergoing liver resection/ ablation for crlm * underwent liver resection/ ablation for crlm, but not their primary tumors exclusion criteria: * non-english speaking * inability to read and/or write * international patients * concurrent malignancy (excluding non-melanoma skin cancers)

Keywords: quality of life hepatectomy 15-057
optimal protein supplementation for critically ill patients

Conditions: Critical Illness

Summary: it is well accepted that during critical illness there is an increase in protein breakdown and loss of lean body mass. previous studies have shown that during critical illness muscle breakdown increases dramatically. the aim of our study is to test the hypothesis that critically ill patients have improved outcomes with higher protein supplementation.


Eligibility criteria:
inclusion criteria: * • medical or surgical patients who are admitted or transferred to the icu with an apache ii score greater than or equal to 18 and who are candidates for enteral nutrition within 48 hours of admission. exclusion criteria: * • patients who cannot tolerate enteral nutrition * patients who have a contraindication for enteral nutrition per american society of enteral and parenteral nutrition guidelines (gi obstruction, intractable nausea and/or vomiting, short bowel syndrome, distal gi fistula, gi bleeding that will require endoscopy, malabsorption that requires tpn, inability to access the gi tract * patients with chronic stage iii or iv kidney disease and/or patients receiving dialysis within six months of this hospital admission as these patients are known to require specific protein diets as an outpatient. patients with acute kidney injury will not be excluded as there is no evidence to suggest these patients require a specific protein diet secondary to their acute kidney injury. * patients with refractory hypotension unresponsive to vasoactive medications * patients who are unlikely to survive the next 48 hours at the time of enrollment (this will be judged by the treating physician) * patients who are unable to give consent and do not have a family member able to give consent on his/her behalf. * patients with end stage liver disease or undergoing liver transplant or liver resection surgery * patients whose physician thinks he/she should not participate * prisoners * pregnant women (all female of childbearing age will have a urine pregnancy test prior to randomization)

Keywords: critically ill protein supplement icu protein synthesis
platelet function in resuscitated patients

Conditions: Acute ST Segment Elevation Myocardial Infarction

Summary: approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due to myocardial infarction. almost all patients are initially diagnosed and treated in the cath lab. therapy usually consists of one or more stent implantations. after implantation of a coronary stent, dual platelet inhibition is necessary for 12 months. insufficient platelet inhibition causes an pronounced increase in risk of stent thrombosis. therefore, knowledge of the individual platelet function is valuable. several factors potentially promote a delayed or reduced mode of action of platelet function inhibitors in resuscitated patients: 1. oral administration is impossible and medication needs to be administered via a gastric line. 2. gastric absorption is delayed after resuscitation 3. according to current guidelines patients are treated with therapeutic hypothermia. including the time of rewarming cooling period is \~48h

patients after successful resuscitation associated to a myocardial infarction will be included into the study the morning after the index event. patients get dual platelet inhibition at the discretion of the interventionist. patients are treated with therapeutic hypothermia according to the local standard operating procedure for 24h and rewarming is performed within an additional 20h. platelet function is measured every morning and aspirin mediated as well as p2y12 (purinergic g protein-coupled receptors-12)-inhibition mediated platelet function inhibition is recorded. all relevant clinical data including apache (acute physiology and chronic health evaluation) and sofa ( sequential organ failure assessment score) scores are collected. the degree of platelet inhibition over time (7 days) and differences between the three drugs tested will be evaluated by optical aggregometry and by using the commercial verifynow test system.

Eligibility criteria:
inclusion criteria: * myocardial infarction * dual platelet inhibition * resuscitation * therapeutic hypothermia exclusion criteria: * none
dopamine in neonate

Conditions: Neonates and Preterm Infants

Summary: the purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of dopamine which is used as treatment of hypotension in neonate and preterm infant.


Eligibility criteria:
inclusion criteria: * admitted at nicu in seoul national university hospital, seoul asan hospital or severance hospital * infants who were diagnosed with hypotension exclusion criteria: * congenital heart disease * chromosomal anomaly * treated with ecmo or crrt * arrhythmia * hypovolemic state
outcome measures in infant/early childhood lung disease w/ chest ct scanning & lung function testing

Conditions: Lung Cancer

Summary: to implement a new method of performing chest ct imaging in young children at packard children's hospital entitled controlled ventilation infant/young child chest ct scanning. this technique will be used to evaluate early lung disease comparing quantitative chest ct air trapping and airway measurements with lung function measurements in infants, toddlers, and young children with chronic lung disease.


Eligibility criteria:
inclusion criteria:1) infants and young children (age \<= 3 months to \< 5 years) and either 2) or 3) below. 2) respiratory condition (e.g. cystic fibrosis (cf), primary ciliary dyskinesia, bronchopulmonary dysplasia, asthma, or other pulmonary condition) and under the care of a pediatric pulmonologist at lpch. 3) oncology condition (e.g. young children with or without cancer, who are being screened for lung metastasis) and are being followed by pediatric oncologists at lpch. 4) for minors, informed consent by parent or legal guardian. 5) ability to comply with study visit procedures as judged by the investigator. exclusion criteria:1) acute wheezing and/or respiratory distress at study visit. 2) acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset in 1 week preceding study visit. 3) oxygen saturation \< 90% on room air at study visit. 4) any medical condition that in the opinion of the investigator precludes subject participation.
carvedilol in hf with preserved ef

Conditions: Heart Failure With Preserved Ejection Fraction; Beta Blocker; Myocardial Strain

Summary: beta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (hfref); but not in those with preserved ef. global longitudinal strain (gls) is a prognostic factor independent of left ventricular ejection fraction (lvef). in a retrospective with 1969 patients with hf and lvef of ≥40%, beta-blocker was associated with improved survival in those with low gls (gls \<14%), but not in those with gls ≥14%. in this prospective, randomized clinical study, the investigators will assess the effect of slow-release carvedilol in patients with hfpef and hypertension. the primary endpoint is the time-averaged proportional changes in nt-probnp level and gls change from baseline to month 6.


Eligibility criteria:
inclusion criteria: * age ≥20 yrs * symptomatic hfpef with lvef≥50% * nt-probnp ≥220 pg/ml (sinus rhythm) or ≥660 pg/ml(af) (bnp ≥80 pg/ml (sinus rhythm) or ≥240 pg/ml(af) ) * sbp≥140mmhg and/or dbp ≥90mmhg, or if taking anti-hypertensive medication, sbp ≥110mmhg. * lavi≥29(sinus rhythm)/34ml/m2 (af) or lvmi≥115(male)/95(female) g/m2 * meet one the following 1. average e/e'≥ 9 2. septal e' \< 7 cm/s 3. lateral e' \<10 cm/s 4. tr velocity \> 2.8 m/s 5. pasp \> 35 mmhg 6. gls \< 16% exclusion criteria: * systolic blood pressure \< 110 mmhg, or heart rate \< 60 beats/min * contra-indication to beta-blockers * creatinine\> 2.4mg/dl * amyloidosis, hypertrophic cardiomyopathy with obstruction, severe aortic or mitral valve disease, acute coronary syndrome, cerebrovascular event within 6 months, pci within 3 months before * ast/alt \>3 x normal upper range

Keywords: hfpef beta-blocker reduced strain bnp
efficacy study of the embryo transfer catheter

Conditions: Infertility (IVF Patients)

Summary: a prospective randomized trial comparing cook k-soft-5100 and frydman classical catheter 4.5 for embryo transfer in human ivf/icsi was performed. three experienced operators participated in the trial, using a fixed distance transfer protocol. primary endpoint was clinical pregnancy rate, secondary endpoints were rates of difficult transfer and of catheter failure. patients were randomized by a computer program immediately prior to embryo transfer.


Eligibility criteria:
inclusion criteria: * patients undergoing embryo transfer in our ivf program between 2000 and 2005 exclusion criteria: * patients not giving consent were excluded